Advantages of DARPins

We developed DARPins to overcome the limitations currently restricting the value of antibodies and other state-of-the-art drugs. The DARPin platform allows the generation of high quality drug candidates at an unseen speed and predictability. These candidates can combine a wide range of valuable and transforming properties:

• Broad target spectrum – DARPins can be engineered to bind to any given target protein


• High affinities – single digit pM affinity without the need for affinity maturation


• Highest potency – a monovalent DARPin can inhibit its target molecule at low pM concentration


• Unmet target selectivity and specificity – DARPins bind their targets with a rigid surface ensuring highest specificity


• High yield microbial production – DARPin GMP production established at 7-10 g/L as soluble protein from E. Coli expression


• Simple architecture - DARPins are small, single domain proteins lacking disulfide bonds


• Site specific modification – Single cysteines can be engineered allowing chemical modification without effecting the binding activity


• High stability – DARPins are heat stable from 60-100°C, are not degraded by proteases and have shelf-lives > 12 months at RT


• Highest solubility – DARPins can be concentrated to >150 g/L without a trace of protein aggregation


• Multiple specificities – DARPins can be engineered to have multiple specificities without losing their beneficial biophysical properties


• Safety/Low immunogenicity – DARPins are of human origin, soluble, stable and are engineered to be free of T-cell epitopes


• Adjustable pharmacokinetics – A toolbox of technologies allows the generation of DARPins with PK profiles ranging from hours to weeks (serum protein binding, PEGylation, Fc coupling)


• Highly effective tumor targeting – The small size and high affinity of DARPins allow ideal tumor penetration and accumulation


• Patient-friendly delivery – DARPins allow for administration via novel delivery routes, including eye-drops or inhalation


• IP – DARPins are not covered by antibody intellectual property


• FTO – Freedom to operate with ribosome display and DARPin libraries